Suppr超能文献

慢性丙型肝炎对干扰素α反应的预测:治疗前变量的统计分析

Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.

作者信息

Camps J, Crisóstomo S, García-Granero M, Riezu-Boj J I, Civeira M P, Prieto J

机构信息

Department of Internal Medicine, Clínica Universitaria, Universidad de Navarra, Pamplona, Spain.

出版信息

Gut. 1993 Dec;34(12):1714-7. doi: 10.1136/gut.34.12.1714.

Abstract

Pretreatment variables that could predict the response of chronic hepatitis C to interferon alfa treatment have not been fully assessed. Eighteen baseline variables were evaluated in a series of 100 consecutive patients treated with a 12 month course of interferon alfa. For the purposes of this study, response was defined as the return to normal of aminotransferase activities before the third month of treatment. Seventy per cent of the patients responded to treatment. Six variables were associated with an increased likelihood of response assessed by univariate analysis. With stepwise multiple regression analysis assessment, however, only three variables remained independently predictive of response: low gamma glutamyltransferase (gamma GT) activities (p < 0.001), absence of obesity (p = 0.005), and absence of cirrhosis (p = 0.01). The response rate in patients with gamma GT activities < 0.66 mu kat/l (n = 55) was 78% and 60% in patients with values > 0.66 mu kat/l (n = 45) (p = 0.048). Response was attained in 75% of non-obese patients (n = 80), compared with only 50% of obese patients (n = 20) (p = 0.03). Finally, 80% of patients without cirrhosis (n = 76) responded, while among those with cirrhosis (n = 24) the response rate was only 37% (p < 0.001). All 23 patients without cirrhosis, <40 years old, and with gamma GT activities <0.66 mu kat/l responded to treatment, while only 28.5% of 14 patients with cirrhosis, >40 years old, and with gamma GT activities >0.66 mu kat/l responded to interferon alfa (p<0.001). Those findings may be useful when evaluating interferon alfa trials and it is suggested that this treatment should be applied early in the course of chronic hepatitis C.

摘要

能够预测慢性丙型肝炎对干扰素α治疗反应的预处理变量尚未得到充分评估。在连续接受12个月干扰素α疗程治疗的100例患者中,对18个基线变量进行了评估。在本研究中,反应被定义为治疗第三个月前转氨酶活性恢复正常。70%的患者对治疗有反应。单因素分析评估显示,有6个变量与反应可能性增加相关。然而,通过逐步多元回归分析评估,只有3个变量仍然独立预测反应:低γ-谷氨酰转移酶(γ-GT)活性(p<0.001)、无肥胖(p = 0.005)和无肝硬化(p = 0.01)。γ-GT活性<0.66μkat/L的患者(n = 55)的反应率为78%,而γ-GT活性>0.66μkat/L的患者(n = 45)的反应率为60%(p = 0.048)。75%的非肥胖患者(n = 80)获得了反应,而肥胖患者(n = 20)中只有50%获得反应(p = 0.03)。最后,无肝硬化的患者(n = 76)中有80%有反应,而有肝硬化的患者(n = 24)中反应率仅为37%(p<0.001)。所有23例无肝硬化、年龄<40岁且γ-GT活性<0.66μkat/L的患者对治疗有反应,而14例有肝硬化、年龄>40岁且γ-GT活性>0.66μkat/L的患者中只有28.5%对干扰素α有反应(p<0.001)。这些发现可能在评估干扰素α试验时有用,并且建议在慢性丙型肝炎病程早期应用这种治疗。

相似文献

引用本文的文献

5
Amantadine therapy for chronic hepatitis C.金刚烷胺治疗慢性丙型肝炎。
J Gen Intern Med. 2004 Jun;19(6):662-8. doi: 10.1111/j.1525-1497.2004.30057.x.
8
Predictors of response to interferon therapy.干扰素治疗反应的预测因素。
Dig Dis Sci. 1996 Dec;41(12 Suppl):115S-120S. doi: 10.1007/BF02087886.

本文引用的文献

2
Impaired monocyte function in liver cirrhosis.肝硬化患者单核细胞功能受损。
Br Med J (Clin Res Ed). 1981 Apr 18;282(6272):1262-3. doi: 10.1136/bmj.282.6272.1262.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验